STOK
Stoke Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +15.9% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 41.15M | $1.35B | +7 | −7 |
| Q1 2026 | 83 | +2 | 38.21M | $1.24B | +9 | −7 |
| Q4 2025 | 80 | -1 | 35.34M | $1.12B | +1 | −2 |
| Q3 2025 | 16 | +1 | 26.41M | $620.57M | +1 | — |
| Q2 2025 | 12 | 0 | 21.43M | $243.28M | +1 | −1 |
| Q1 2025 | 9 | -3 | 5.10M | $33.93M | — | −3 |
| Q4 2024 | 12 | +1 | 4.31M | $47.51M | +2 | −1 |
| Q3 2024 | 10 | +2 | 3.11M | $38.25M | +3 | −1 |
| Q2 2024 | 8 | — | 2.69M | $36.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 1.67M | +43.9% | $20.53M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Marshall Wace ✦ | 1.67M | +43.9% | $20.53M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 870.83K | +9.7% | $10.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 870.83K | +9.7% | $10.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 171.25K | +25.0% | $2.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 136.97K | -4.6% | $1.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 136.97K | -4.6% | $1.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 116.68K | +1.5% | $1.43M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 75.09K | New | $922,843 | 0.0% | New | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 75.09K | New | $922,843 | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 75.09K | New | $922,843 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 35.24K | +0.6% | $434,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Millennium Management ✦ | 14.84K | -94.9% | $182,322 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 13.34K | New | $163,912 | 0.0% | New | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 6.95K | New | $85,416 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $922,843 | 0.0% |
| AQR Capital Management | $922,843 | 0.0% |
| AQR Capital Management | $922,843 | 0.0% |
| Arrowstreet Capital | $163,912 | 0.0% |
| Citadel Advisors | $85,416 | 0.0% |
Exited
| Renaissance Technologies | $151,312 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 196 holders, 69.25M shares, $2.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.72K sh · $86,932
Officer · 145 sh · $4,708
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology